Special Issue "Stem Cell Research on Cardiology: Series 2"
Deadline for manuscript submissions: 30 June 2021.
2) Dept. Life, Light & Matter, Interdisc. Faculty, University of Rostock, Rostock, Germany
Interests: cardiovascular diseases; pluripotent stem cells; ESCs; iPSCs; adult stem cells; cell replacement; direct reprogramming; cardiac regeneration; stem cell optimisation; cell targeting; sinus node; biological pacemaker; cell therapy; gene therapy; forward programming; direct reprogramming; organoid; disease-in-the-dish
Special Issues and Collections in MDPI journals
Cardiovascular diseases are the leading cause of death in developed countries with very limited therapeutic options. A major cause lies in the very restricted regenerative capacity of terminally differentiated cardiomyocytes post injury – therefore novel approaches toward cardiac regenerative therapy is highly desired. Following injury oft, the myocardium, resident cardiac fibroblasts, representing over 50% of the cells in the heart, start to proliferate and produce an extracellular matrix, which will ultimately lead to fibrosis and heart failure. A large number of preclinical and clinical trials have shown stem cell therapy to be a promising therapeutic approach for the treatment of cardiovascular diseases. Since the first transplantation into human patients, several stem cell types have been applied in this field, including bone marrow-derived stem cells, cardiac progenitors as well as embryonic and induced pluripotent stem cells and their derivatives. In addition, the novel field of direct cardiac reprogramming brought promising advances in vitro and in vivo, opening an additional future field for cardiovascular regenerative medicine. In order to optimize these approaches, it will be crucial to elucidate the underlying mechanisms mediating the beneficial effects of stem cell transplantation or direct reprogramming. Based on these mechanisms, scientists have begun to develop different improvement strategies to boost the potency of stem cell repair and to generate the "next generation" of cell-based therapeutics. Programming success, homogeneity, and integrity of cells will further benefit from state-of-the-art single-cell-NGS technology. The current Special Issue will accept original studies, reviews, and technical reports in the field of cardiovascular stem cell biology and reprogramming, written by scientists active in the field.
Prof. Robert David
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cardiovascular diseases
- Pluripotent stem cells
- Adult Stem Cells
- Cell replacement
- Direct Reprogramming
- Cardiac regeneration
- Stem cell optimisation
- Cell Targeting
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Conditioned medium from mesenchymal stem cells alleviates endothelial dysfunction of vascular grafts submitted to ischemia/reperfusion injury in 15-month-old rats
Sevil Korkmaz-Icöz1; Xiaoxin Sun1; Shiliang Li1; Paige Brlecic1; Sivakkanan Loganathan1; Mihály Ruppert1,2, Alex Ali Sayour1,2; Tamás Radovits2; Matthias Karck1; Gábor Szabó1,3
Background In patients undergoing coronary artery bypass graft surgery (CABG) ischemia/reperfusion injury (IRI) is the main contributor to organ dysfunction. Aging-induced vascular damage may be further aggravated during CABG. Beneficial effects of conditioned medium (CM) from bone marrow-derived mesenchymal stem cells (MSCs) have been suggested in an experimental model of IRI. We hypothesized that physiological saline-enriched with CM would protect vascular grafts from IRI in 15-month-old rats.
Mesenchymal stem cell-conditioned medium prevents endothelial dysfunction of vascular grafts with ischemia/reperfusion injury in diabetic rats
Sevil Korkmaz-Icöz1, Gianluca Sistori1, Sivakkanan Loganathan1, Paige Brlecic1, Tamás Radovits2, Mihály Ruppert1,2, Alex Ali Sayour1,2, Maik Brune3, Matthias Karck1, Gábor Szabó1,4
Background Ischemia/reperfusion injury (IRI) remains a challenge in coronary artery bypass surgery (CABG). Diabetes mellitus (DM)-induced vascular damage may be further exacerbated by IRI. Therefore, diabetic patients requiring CABG may run a high risk for cardiovascular complications. Beneficial effects of mesenchymal stem cell-conditioned medium (CM) have been shown against IRI. We hypothesized that physiological saline supplemented with CM protects vascular grafts from IRI in diabetic rats.